<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13482">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394524</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00021877</org_study_id>
    <secondary_id>IRB 830-2005</secondary_id>
    <nct_id>NCT00394524</nct_id>
  </id_info>
  <brief_title>Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU</brief_title>
  <official_title>Comparative Trial Between a Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grady Memorial Hospital, Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Piedmont Hospital, Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood sugars increase the risk of complications and death in diabetic patients admitted
      to the hospital. Recent studies hve shown that strict blood sugar control with intravenous
      (IV) insulin lowers the risk of such complications and death in the ICU. Several insulin
      infusion protocols have been reported in the literature, but it is not known which is the
      best. These protocols use tables and formulas that may be confusing and difficult to follow.
      To facilitate patient care, insulin protocols could be placed on a computer and used at the
      patient's bedside to direct the nursing staff administering the IV insulin. The Glucommander
      is one of such computer-derived insulin infusion protocol which has been used successfully
      in patients with diabetes since 1984. We hypothesize that management of inpatient
      hyperglycemia with a computer-guided intravenous infusion protocol will facilitate smoother
      glycemic control with a lower rate of low blood sugars than treatment following a standard
      insulin infusion algorithm in the medical intensive care unit. We will aim to determine
      differences in glycemic control between treatment with a computer-guided intravenous
      infusion protocol (Glucommander) and a standard insulin infusion algorithm in critically ill
      patients in the ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Summary:

      Increasing evidence from observational studies in hospitalized patients with and without
      diabetes indicates that hyperglycemia is a predictor of poor outcome. Blood glucose control
      with intensive insulin therapy in patients with acute critical illness reduces the risk of
      multiorgan failure and systemic infection, and decreases short- and long-term mortality.

      The use of intravenous insulin infusion is the preferred route of insulin administration for
      the management of diabetic subjects with diabetic ketoacidosis and nonketotic hyperosmolar
      state, intraoperative and postoperative care, the postoperative period following heart
      surgery and organ transplantation, acute myocardial infarction, stroke, and critical care
      illness. Some of these settings may be characterized by, or associated with, severe or
      rapidly changing insulin requirements, generalized patient edema, impaired perfusion of
      subcutaneous sites, requirement for pressor support, and/or use of total parenteral
      nutrition. In these settings, the intravenous route for insulin administration has been
      considered superior than the subcutaneous injection of split-mixed regimen of intermediate
      and regular insulin with respect to rapidity of effect in controlling hyperglycemia, overall
      ability to achieve glycemic control, and most importantly, preventing hypoglycemic episodes.
      Recently, several insulin infusion protocols have been reported in the literature; these
      algorithms and formulas, however, may be confusing and difficult to follow and may increase
      the risk of dosing errors. To facilitate patients care, insulin algorithms could be placed
      on a computer and used at the patient bedside to direct the nursing staff administering the
      intravenous insulin. The Glucommander is one of such computer-derived insulin infusion
      protocol which has been used successfully in over 5,802 patients with diabetes between 1984
      and 1998. We hypothesize that management of inpatient hyperglycemia with a computer-guided
      intravenous infusion protocol will facilitate smoother glycemic control with a lower rate of
      hypoglycemic events than treatment following a standard insulin infusion algorithm in
      critically ill patients in medical the ICU. We will aim to determine differences in glycemic
      control between treatment with a computer-guided intravenous infusion protocol
      (Glucommander) and a standard insulin infusion algorithm in critically ill patients in the
      ICU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Glucose</measure>
    <time_frame>daily mean blood glucose during the insulin infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>glucose in mg/dl assessed with inpatient calibrated glucometers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences Between Treatment Groups in Hypoglycemia</measure>
    <time_frame>daily</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>mean number of days in the ICU during the hospital stay</time_frame>
    <safety_issue>No</safety_issue>
    <description>average number of days in the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hospital Length of Stay in Days</measure>
    <time_frame>during the entire hospitalization</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean number of days in the hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Diabetes or With New Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucommander computer assisted insulin infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glulisine insulin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucommander</intervention_name>
    <description>Computer-guided IV insulin infusion (Glucommander)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard insulin infusion drip</intervention_name>
    <description>Insulin infusion with glulisine per columnar algorithm</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucommander</intervention_name>
    <description>Glucommander computer assisted program to run glulisine insulin drip</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glulisine drip using columnar algorithm</intervention_name>
    <description>Apidra insulin per insulin infusion algorithm</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 70 years admitted to a medical ICU

          2. A known history of diabetes mellitus or with new hyperglycemia untreated or treated
             by diet, insulin therapy or with any combination of antidiabetic agents
             (sulfonylureas, metformin, thiazolidinediones).

               -  Blood glucose greater than 120 mg/dl on ≥ 2 occasions for known, treated
                  diabetics or greater than 140 mg/dl on ≥ 2 occasions for those with new
                  hyperglycemia.

          3. Subjects must have an admission blood glucose &lt; 400 mg/dL, without laboratory
             evidence of diabetic ketoacidosis (serum bicarbonate &lt; 18 milliequivalents/L or
             positive serum or urinary ketones).

        Exclusion Criteria:

          1. Subjects with acute hyperglycemic crises such as diabetic ketoacidosis (DKA) and
             hyperosmolar hyperglycemic state [38].

          2. Patients with known HIV, severely impaired renal function (serum creatinine ≥3.0
             mg/dl).

          3. Patients with mental condition rendering the subject unable to understand the nature,
             scope, and possible consequences of the study.

          4. Female subjects who are pregnant or breast feeding at time of enrollment into the
             study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM/Grady Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Bode, MD</last_name>
    <role>Study Director</role>
    <affiliation>Piedmont Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abbas E Kitabchi, PhD,MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Tennessee Health Science Center, Memphis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irl B Hirsch, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hopsital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center, Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Newton CA, Smiley D, Bode BW, Kitabchi AE, Davidson PC, Jacobs S, Steed RD, Stentz F, Peng L, Mulligan P, Freire AX, Temponi A, Umpierrez GE. A comparison study of continuous insulin infusion protocols in the medical intensive care unit: computer-guided vs. standard column-based algorithms. J Hosp Med. 2010 Oct;5(8):432-7. doi: 10.1002/jhm.816.</citation>
    <PMID>20945468</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2006</firstreceived_date>
  <firstreceived_results_date>December 8, 2008</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ICU</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>glucommander</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>4 hospital centers between October 2006 and July 2008.</recruitment_details>
      <pre_assignment_details>Some patients were consented for the trial, however withdrew prior to initiation of active arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glucommander</title>
          <description>continuous insulin infusion per Glucommander, a computer-guided device; dosage or rate of insulin per algorithm</description>
        </group>
        <group group_id="P2">
          <title>Standard Insulin Infusion</title>
          <description>standard continuous insulin infusion with columnar algorithm; dosage or rate of insulin per algorithm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glucommander</title>
          <description>insulin infusion per Glucommander</description>
        </group>
        <group group_id="B2">
          <title>Standard Insulin Infusion</title>
          <description>standard insulin infusion with columnar algorithm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
                <measurement group_id="B2" value="78"/>
                <measurement group_id="B3" value="157"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="114"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57.4" spread="11"/>
                <measurement group_id="B2" value="58" spread="14"/>
                <measurement group_id="B3" value="57.7" spread="12.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="88"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="69"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
                <measurement group_id="B2" value="78"/>
                <measurement group_id="B3" value="157"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Glucose</title>
        <description>glucose in mg/dl assessed with inpatient calibrated glucometers</description>
        <time_frame>daily mean blood glucose during the insulin infusion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Glucommander</title>
            <description>insulin infusion per Glucommander</description>
          </group>
          <group group_id="O2">
            <title>Standard Insulin Infusion</title>
            <description>standard insulin infusion with columnar algorithm</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Glucose</title>
            <description>glucose in mg/dl assessed with inpatient calibrated glucometers</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102.6" spread="9"/>
                  <measurement group_id="O2" value="120.6" spread="16.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences Between Treatment Groups in Hypoglycemia</title>
        <time_frame>daily</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay</title>
        <description>average number of days in the intensive care unit</description>
        <time_frame>mean number of days in the ICU during the hospital stay</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Glucommander</title>
            <description>insulin infusion per Glucommander</description>
          </group>
          <group group_id="O2">
            <title>Standard Insulin Infusion</title>
            <description>standard insulin infusion with columnar algorithm</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Intensive Care Unit (ICU) Stay</title>
            <description>average number of days in the intensive care unit</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" spread="13.7"/>
                  <measurement group_id="O2" value="9.34" spread="9.44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hospital Length of Stay in Days</title>
        <description>mean number of days in the hospital</description>
        <time_frame>during the entire hospitalization</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Glucommander</title>
            <description>insulin infusion per Glucommander</description>
          </group>
          <group group_id="O2">
            <title>Standard Insulin Infusion</title>
            <description>standard insulin infusion with columnar algorithm</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Hospital Length of Stay in Days</title>
            <description>mean number of days in the hospital</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.0" spread="14.7"/>
                  <measurement group_id="O2" value="24.5" spread="26.18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glucommander</title>
          <description>insulin infusion per Glucommander</description>
        </group>
        <group group_id="E2">
          <title>Standard Insulin Infusion</title>
          <description>standard insulin infusion with columnar algorithm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
